Novo Nordisk and Eli Lilly ramped up lobbying efforts when US legislators targeted insulin prices

When legislators began seriously thinking about insulin prices in the US, Novo Nordisk and Eli Lilly responded by increasing their lobbying contributions.

Photo: Novo Nordisk & Ritzau Scanpix/Reuters/Vincent Kessler

In 2021, when work began on legislation pertaining to the insulin prices in the US, Novo Nordisk and US-based Eli Lilly intensified their lobbying efforts, as reported by media Stat.

According to the media, legislators started drawing up plans for a ceiling for how much individual patients could be required to pay for their insulin out of pocket.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs